Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy by E Neely et al.
Neely et al. International Journal of Pediatric Endocrinology 2013, 2013:20
http://www.ijpeonline.com/content/2013/1/20RESEARCH Open AccessRandom unstimulated pediatric luteinizing
hormone levels are not reliable in the assessment
of pubertal suppression during histrelin
implant therapy
E Kirk Neely1*, Lawrence A Silverman2, Mitchell E Geffner3, Theodore M Danoff4, Errol Gould4 and Paul S Thornton5Abstract
Background: Gonadotropin-releasing hormone agonist (GnRHa)-stimulated luteinizing hormone (LH) is the
standard hormonal assessment for both diagnosis and therapeutic monitoring of children with central precocious
puberty (CPP). Use of unstimulated (random) LH levels may be helpful in diagnosis and has gained popularity in
monitoring GnRHa therapy despite lack of validation against stimulated values. The objective of this investigation
was to assess the suitability of random LH for monitoring pubertal suppression during GnRHa treatment.
Methods: Data from a multi-year, multicenter, open-label trial of annual histrelin implants for CPP was used for our
analysis. Children meeting clinical and hormonal criteria for CPP, either naïve to GnRHa therapy or previously treated
with another GnRHa for at least 6 months who were being treated at academic pediatric centers were included in
the study. Subjects received a single 50-mg subcutaneous histrelin implant annually until final explant at an age
determined at the discretion of each investigator. Monitoring visits for physical examination and GnRHa-stimulation
testing were performed at regular intervals. The main outcome measure was pubertal suppression during treatment
defined by peak LH < 4 mIU/mL after GnRHa stimulation.
Results: During histrelin treatment, 36 children underwent a total of 308 monitoring GnRHa stimulation tests.
Unstimulated and peak LH levels were positively correlated (r = 0.798), and both declined from the first to second
year of treatment. Mean ± SD peak LH level during therapy was 0.62 ± 0.43 mIU/mL (range, 0.06–2.3), well below
the normal prepubertal mean. Mean random LH was 0.35 ± 0.25 mIU/mL (range, 0.04–1.5), 10-fold higher than the
normal prepubertal mean. The random LH levels were above the prepubertal upper threshold (<0.3 mIU/mL) in
48.4% of all tests and in 88.9% of subjects at some point during therapy.
Conclusions: In contrast with GnRHa-stimulated LH, unstimulated LH values frequently fail to demonstrate
suppression to prepubertal values during GnRHa therapy for CPP, despite otherwise apparent pubertal suppression,
and are thus unsuitable for therapeutic monitoring.
Trial registration: ClinicalTrial.gov NCT00779103.
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Gonadotropin-releasing hormone agonist (GnRHa) ther-
apy is considered the standard of care for treatment of chil-
dren with central precocious puberty (CPP) [1]. Monthly
and 3-monthly depot leuprolide [2-5] and the annual his-
trelin implant [6,7] are the most commonly used therapies
in the U.S. Serum LH response to GnRH or GnRHa stimu-
lation, typically using aqueous leuprolide acetate as the
stimulating agent, is the conventional test used to diagnose
CPP [8-15] in conjunction with sex steroid levels and char-
acteristic clinical features. Unstimulated, i.e. random, LH
levels can also be used for diagnosis of CPP, although with
limited sensitivity in early puberty [16].
During treatment of CPP, GnRHa stimulation tests are
utilized to monitor and confirm continued LH suppression,
with peak levels dropping into or below the normal pre-
pubertal range [2-7,17,18]. During depot GnRHa therapy,
stimulation testing can be performed easily by drawing a
post-injection sample, whereas monitoring during histrelin
implant therapy requires an additional injection. Many
practitioners alternatively use a random LH level during
therapeutic monitoring instead of stimulation testing, des-
pite the lack of data demonstrating its utility. Here we in-
vestigate the suitability of random LH levels for assessment
of pubertal suppression during histrelin implant therapy
using data collected from the pivotal, long-term, U.S. mul-
ticenter trial of histrelin for treatment of CPP [6,7].
Methods
Data were derived from an open-label study of 36 chil-
dren with CPP [6,7] in which all subjects received a 50-
mg subcutaneous histrelin implant (Supprelin LA, Endo
Pharmaceuticals, Malvern, PA) in the upper arm annu-
ally until final explant at an age determined at the dis-
cretion of each investigator. The study was open to girls
aged 2–8.99 years and to boys aged 2–9.99 years who
had evidence of CPP and who had not previously re-
ceived GnRHa therapy (“treatment naïve”) and to girls
aged 2–10.99 years and boys aged 2–11.99 years who
had received treatment with a GnRHa regimen for at
least 6 months (“previously treated”). Prior to any treat-
ment, all participants had breast Tanner stage ≥ 2 (girls)
or testicular volume ≥ 4 mL (boys), stimulated LH > 7
mIU/mL after GnRH or > 10 mIU/mL after leuprolide
acetate, and bone age ≥ +2 standard deviations [SD].
Written informed consent was obtained at each site, as
was assent when appropriate.
Monitoring visits with physical examinations and hor-
mone testing were performed at months 1, 3, 6, 9, 12, 13,
18, 24, 36, and every 6 months thereafter. Blood samples
were collected at 0 minutes (baseline) before subcutane-
ous injection of leuprolide acetate (20 μg/kg) and 30 and
60 minutes post-injection; beginning in the third year of
the study, samples were obtained at 0 and 40 minutes. Allhormone measurements were performed at Esoterix Clin-
ical Trial Services (East Windsor, NJ). LH and follicle-
stimulating hormone (FSH) were measured by immuno-
chemiluminescent (ICMA) assay with a lower limit of
quantification of 0.02 mIU/mL [15]. Mean values are
stated with standard deviations. Estradiol was initially
measured on baseline samples using radioimmunoassay
(RIA) with a lower limit of detection of 5 pg/mL, but,
beginning in the third year of the study, assays were per-
formed by liquid chromatography and tandem mass spec-
trometry (LCMS/MS) with a lower limit of 1 pg/mL. For
consistency of data analysis, any estradiol value ≤ 5 pg/mL
was imputed as 5 pg/mL. Testosterone measurement was
performed on baseline samples using RIA with a lower
limit of 3 ng/dL.
Results
Mean age at the onset of GnRHa therapy was 7.1 ± 1.4 years
in the treatment-naïve group (n = 20) and 8.9 ±1.5 years in
the previously treated group (n = 16). Mean ± SD unstimu-
lated (0 minute) and peak stimulated (30 or 60 minute)
LH levels on the day of initial implant were 1.54 ± 1.67
mIU/mL and 28.2 ± 20 mIU/mL, respectively, in the naïve
group, and 0.36 ± 0.33 mIU/mL and 2.09 ± 2.15 mIU/mL,
respectively, in the pretreated group. Duration of implant
therapy ranged from 1 to 5 years. There were no treatment
failures or withdrawals for adverse events.
Baseline pretreatment testing provided valuable adjunct
data regarding the possible lack of utility of random LH
values in both the diagnosis of CPP and its monitoring.
Prior to the initial implant, 7/20 (35%) treatment-naive
subjects had prepubertal 0 minute LH levels (< 0.3
mIU/mL) despite peak GnRHa-stimulated LH levels diag-
nostic of CPP (> 10 mIU/mL), demonstrating the relatively
limited sensitivity of a random LH to diagnose CPP. Also,
6/16 (38%) of previously treated patients on depot leupro-
lide at the time of implant had unstimulated LH levels > 0.3
mIU/mL (range, up to 1.1 mIU/mL) at the baseline visit.
During histrelin treatment, a total of 308 GnRHa
stimulation tests were performed in the 36 children. All
subjects in both groups maintained suppression of LH
levels for the duration of the study based on the primary
outcome measure of peak GnRHa-stimulated LH < 4
mIU/mL. The mean of all peak LH levels obtained dur-
ing the leuprolide stimulation tests while on therapy was
0.62 ± 0.43 mIU/mL (range, 0.06–2.3 mIU/mL). Levels at
30 and 60 minutes were not significantly different from
one another. In females, all estradiol levels drawn at
stimulation testing were below the a priori threshold of
20 pg/mL, and in boys all testosterone levels were below
the a priori testosterone threshold of 30 ng/dL.
The mean of all 0 minute LH levels obtained in leupro-
lide stimulation tests during therapy was 0.35 ± 0.25






















































Figure 2 Mean (± SE) unstimulated LH levels (0 minutes) at
each visit over 5 years of histrelin therapy. The horizontal
dashed line indicates the 0.3 mIU/mL pubertal threshold for
unstimulated LH levels [15]. Note that the time scale is not
proportionate. SE is not shown beginning with the 36-month visit
due to small sample size, and values in the fifth year are not shown
due to small sample size (3 or less).
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leuprolide-stimulated LH levels (r = 0.798, Figure 1) (ran-
dom LH values did not correlate with estradiol or peak
FSH). Despite the fact that all peak LH levels were sup-
pressed to < 2.5 IU/L, random LH levels remained at or
above the pubertal threshold of 0.3 mIU/mL in 149/308
tests (48.4%) and were ≥ 0.7 mIU/mL in 28/308 (9.1%)
and ≥ 1.0 mIU/mL in 7/308 (2.3%). The seven values ≥ 1.0
mIU/mL occurred in 7 different children, and only 4/36
children (11.1%) had random LH< 0.3 at all treatment visits
(1/20 naïve, 3/16 previously treated).
A temporal decline in both random and peak LH
(Figure 2) was observed over the course of study. Mean
random LH levels in the first and subsequent years were
0.42 ± 0.27 mIU/mL (n = 174) and 0.25 ± 0.19 mIU/mL
(n = 141), respectively. The highest random LH value
was 1.5 mIU/mL during year one, compared with 1.0
mIU/mL during years 2 to 5. Of the 28 basal LH values >
0.7 IU/L during therapy, 24 occurred in the first year.
Mean random LH levels were slightly higher in the naïve
group compared with the previously treated group during
the first year of implant therapy. Six out of 7 random LH
values > 1 mIU/mL occurred in the naïve group in the first
year of therapy. After the first year, the mean random LH
levels in the 2 groups were not different.
Discussion
All study subjects on histrelin implant therapy for CPP
were clinically and biochemically suppressed using the
standard outcome measures of peak LH returning to pre-
pubertal levels, reduced sex steroid levels, cessation of ad-






























Figure 1 Scattergram of unstimulated versus peak
GnRHa-stimulated LH levels during the histrelin implant therapy.
Data from all follow-up visits (n = 308) during the first year of
histrelin implant therapy (open circles) and the second through
fifth year of therapy (solid circles) are shown. The horizontal
dashed line represents the a priori peak GnRHa-stimulated LH
threshold level of 4 mIU/mL defining adequate suppression. The
vertical dashed line indicates the published 0.3 mIU/mL pubertal
threshold for unstimulated LH levels [15].and reduction in the rate of bone age advancement [6,7].
In this multi-year study of 36 children treated with histre-
lin implants (20 naïve to treatment and 16 pretreated with
another GnRHa), all peak LH values during implant ther-
apy were < 2.5 mIU/mL, demonstrating that puberty in all
subjects was unequivocally suppressed. Nonetheless, the
random unstimulated LH value exceeded the 0.3 mIU/mL
pubertal threshold for the Esoterix assay at 48.4% of the
treatment visits, the value was sporadically > 1 mIU/mL in
7 different children, and the lack of suppression assessed
by random LH was nearly universal, occurring in 89% of
children, despite every other parameter indicating pubertal
suppression.
In other words, stimulated LH returns to prepubertal
norms during histrelin therapy, but random unstimulated
LH levels do not, making the usefulness of random LH in
therapeutic monitoring somewhat dubious. The physiologic
reason for persistence of basal LH in the pubertal range is
not understood. GnRH superagonist therapy might result
in tonic LH secretion, but the observed decline over years
of therapy would need to be explained. Alternatively, con-
sistently low but measurable LH might be related to the cir-
culating alpha subunits during therapy, although modern
assays do not cross-react with those subunits.
Persistence of pubertal random LH values was reported
in short-term depot leuprolide therapy nearly 2 decades
ago when ultrasensitive LH assays became available [15,16].
It was again recently noted during short-term histrelin ther-
apy [19]. That study was performed with a much smaller
sample size, non-simultaneous random and stimulated LH
testing, and a relatively insensitive LH assay, but the mes-
sage is effectively the same. Nonetheless, random LH
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ion to confirm suppression. The persistent elevation in ran-
dom LH and the temporal decline during the first years of
therapy have also been observed during long-term depot
leuprolide therapy [2]. It is likely not coincidental that the
mean random LH level in the previously treated group in
our study was essentially unchanged by subsequent histre-
lin therapy. Persistent elevation of the random LH level
is characteristic of both leuprolide and histrelin therapy,
whereas a three-fold reduction in peak LH levels was seen
following the change in our pretreated subjects from depot
leuprolide to histrelin implant.
Unstimulated LH values trended lower during succes-
sive years of histrelin therapy, as did the GnRHa-
stimulated LH levels [7]. Our data confirm that random
LH levels during GnRHa therapy correlate positively
with stimulated LH levels. Nevertheless, a considerable
percentage of random LH levels remained at or well
above the pubertal threshold in the later years of histre-
lin treatment. The mean random LH of 0.35 mIU/mL
during therapy remained approximately 10-fold higher
than the prepubertal mean for this LH ICMA assay,
0.03 ± 0.03 mIU/mL [15], even in the later years of ther-
apy. This extremely low prepubertal norm for random
LH using an accurately performed ICMA has been cor-
roborated by other assays [18].
In comparison with the continued elevation of random
LH levels, the mean peak LH of 0.62 mIU/mL during ther-
apy in the current study is markedly less than the normal
mean prepubertal peak LH (2.0 ± 1.5 mIU/mL) for this
ICMA assay [15]. Mean GnRHa-stimulated levels in the
later years of therapy fall to near-equivalence with random
LH levels. These findings imply that chronic GnRH supera-
gonist therapy results in low-level tonic LH secretion, but
nearly complete suppression of pulsatility. As a conse-
quence, only the GnRHa-stimulated LH level during ther-
apy provides clear biochemical confirmation of suppression
of the pubertal axis.
During histrelin therapy, assessment of peak LH re-
quires an aqueous leuprolide injection, unlike GnRHa in-
jection therapies in which the therapeutic injection itself
can be used as the stimulating agent [4,17,18]. Thus, it is
not surprising that some practitioners have been using un-
stimulated LH levels for convenience or cost savings in
monitoring histrelin therapy, along with clinical features
and random sex steroid levels. Some utilize 24-hour
leuprolide-stimulated estradiol, which circumvents estra-
diol assay limitations but is likely more inconvenient to
obtain than stimulated LH because of the necessity of a re-
turn visit. A consensus statement 5 years ago on pediatric
uses of GnRHa [1] did not take a position on the utility of
random LH for monitoring because the practice was com-
mon and published data using sensitive LH assays were at
that time limited. Our findings clearly demonstrate thatthe practice of relying upon random LH for monitoring
should be used cautiously, if at all.
Conclusions
In this study of 36 children, no treatment failures occurred
during histrelin implant therapy as assessed by leuprolide
stimulation testing and by clinical parameters such as ces-
sation of pubertal progression and diminished growth vel-
ocity. Considering that 89% of these subjects exhibited a
random LH in the pubertal range at some point during
therapy, random LH is unsuitable for routine therapeutic
monitoring. A two-step test sequence of random LH
followed by as-needed stimulation testing seems futile
when failure of the first test is so common. An argument
can be made that clinical parameters alone (particularly
slowing of growth and decrease in breast size) suffice for
treatment monitoring, at least during histrelin therapy. A
GnRHa stimulation test with estradiol should be per-
formed if laboratory confirmation is desired, specifically if
there are doubts about clinical suppression.
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